Calderón JAG

Language: Spanish
References: 10
Page: 189-193
PDF size: 48.94 Kb.

ABSTRACT

More than 60% of patients infected will be disable o will have problems with their normal activity [9]. Take into account risk factors such as the age, females because this could contribute to a longer duration of symptoms and that patients with preexisting arthralgia and or osteoarthritis will have a higher risk of persisting symptoms [9]. A higher viral load will produce more inflammatory substances in acute stages [2]. Taking into account the posibility of reemerging of this virus and the survival caracteristics prevent the infections and have support to be able to treat it. Infection with this virus will leave a longlife immunity [2]. There is no vaccine for Chikungunya [10].

REFERENCES

1. Burt F, Rolph M, Rulli N, Mhalingam S, Heise M. Chikungunya: a reemerging virus. The Lancet 2012; 379: 662-671.

2. Chen L, Wilson M. Dengue and Chikungunya in Travelers: recent update. Current Opinion 2012; 25: 523-529.

3. Caglioti C, Lalle E, Castilleti C, et al. Chikungunya Virus Infection: An Overview. New Microbiologica 2013; 36: 211-227.

4. Kaur P, Jang Han Chu J. Chikungunya virus: an update on antiviral development and challenges. Drug Discovery Today 2013; 18: 969-983.

5. Kucharz E, Cebula-Byrska I. Chikungunya Fever Review Article. European Journal of Internal Medicine 2012; 23: 325-329.

6. Montero A. Fiebre Chikungunya- Una nueva amenaza global. Medicina clínica 2014: 1-

7. MacFadden D, Bogoch I. Five Things To know About Chikungunya. CMAJ 2014; 186: 775.

8. Ross RW. The Newala Epidemic. The Virus Isolation: Pathogenic properties and Relationship to The Epidemic. J Hyg 1956; 54: 177-191.

9. Thiberville S, Moyen N, Dupis L, Nougairede A, et al. Chikungunya Fever: Epidemiology, Clinical Syndrome, Pathogenesis and Therapy. Antiviral Research 2013; 99: 345’370.

10. Weaver S, Osorio J, Livengood J, Chen R, Stinchcomb D. chikungunya Virus and Prospects for a Vaccine. NIH Public Access 2012; 11: 1087- 1101.